OINDPnews


Proveris Scientific

Business

Meda to be acquired by Mylan

Mylan has announced that it will acquire Meda, which markets a number of OINDPs, including Dymista, Astelin, and Astepro nasal sprays; the Aerospan MDI; and the Novopulmon Novolizer and Formatris Novolizer DPIs. Meda had previously rejected acquisition by Mylan, but the Meda board now recommends that shareholders accept the offer, which is valued at SEK 60.3 billion … [Read more...] about Meda to be acquired by Mylan

Fraunhofer ITEM acquires Takeda inhaled surfactant technology

The Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) has acquired Takeda's Surfactant and Continuous Powder Aerosolization (CPA) program, the company said. According to the announcement, the transfer took place as Takeda shut down its respiratory department; Takeda sold its core respiratory business to AstraZeneca in December 2015. According … [Read more...] about Fraunhofer ITEM acquires Takeda inhaled surfactant technology

Rhinocort nasal spray now available over the counter in the US

Johnson & Johnson subsidiary McNeil Consumer Healthcare says that Rhinocort budesonide nasal spray is now available over the counter in the US for the treatment of allergic rhinitis. McNeil acquired the OTC rights to AstraZeneca's Rhinocort Aqua in 2014. McNeil Consumer Healthcare Group Brand Director Purvi Farahi commented, “For consumers who are suffering from … [Read more...] about Rhinocort nasal spray now available over the counter in the US

Septodont to promote Egalet’s Sprix nasal spray to US dentists

Egalet Corporation has announced that it has partnered with Septodont, Inc. to promote Sprix ketorolac tromethamine nasal spray to US dentists. Septodont will pay Egalet an undisclosed licensing fee up front, sales-based milestones and a share of profits from net sales. Sprix was approved by the FDA in 2010 for short-term treatment of moderate-to-severe pain. Its … [Read more...] about Septodont to promote Egalet’s Sprix nasal spray to US dentists

MannKind says it may partner on Afrezza but will retain full rights

MannKind Corporation held an investor call on February 3, 2016 in which CEO Matt Pfeffer said that the company might co-promote Afrezza inhaled insulin with a partner or partners after Sanofi returns the rights, but that MannKind would retain full rights to the product and will market Afrezza itself after the transition, which is anticipated to occur around April 5, … [Read more...] about MannKind says it may partner on Afrezza but will retain full rights

Spiriva Respimat now available in the US for the treatment of asthma

Spiriva Respimat is now available in US pharmacies for the treatment of asthma, Boehringer Ingelheim has announced. The FDA approved Spiriva Respimat for the treatment of asthma in patients aged 12 and older in September 2015. The tiotropium bromide soft mist inhaler was approved by the FDA for the treatment of COPD in September 2014 and has been available in the … [Read more...] about Spiriva Respimat now available in the US for the treatment of asthma

OptiNose selected for Norwegian grant to study intranasal narcolepsy therapy

OptiNose has been selected by the Research Council of Norway for a grant of up to NOK 15.9 million ($1.8 million) to study intranasal delivery of Orexin-A for the treatment of narcolepsy. The grant is contingent on reaching a contract agreement between the Research Council, OptiNose, and its partners, which include Oslo University Hospital, Smerud Medical Research, … [Read more...] about OptiNose selected for Norwegian grant to study intranasal narcolepsy therapy

Mundipharma to market Flutiform in Central and South America, Mexico

Skyepharma has announced agreements with Sanofi and Mundipharma that will transfer Mexican, Central American, and South American development, licensing and marketing rights for the Flutiform fluticasone/formoterol MDI to Mundipharma. Sanofi will continue to manufacture Flutiform at its Holmes Chapel, UK facility. Sanofi licensed those rights from Skyepharma in 2011 … [Read more...] about Mundipharma to market Flutiform in Central and South America, Mexico

Mucosis gets €3.7 million grant for development of intranasal RSV vaccine

Dutch intranasal vaccine developer Mucosis has received €3.7 million from the Wellcome Trust for clinical development of its SynGEM intranasal respiratory syncytial virus (RSV) vaccine, the company said. The money will be used to fund a Phase 1 dose-finding study and a Phase 2 challenge study conducted by researchers from the National Heart & Lung Institute, Imperial … [Read more...] about Mucosis gets €3.7 million grant for development of intranasal RSV vaccine